Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by ElMaestro  – Denmark, 2019-04-05 06:22 (772 d 14:36 ago) – Posting: # 20123
Views: 2,568

Hi sury,

» Can we use the pharmacokinetic parameter ISCV for the sample size estimation for the clinical endpoint bioequivalence study?

That is a catastrophic approach. It will most likely lead to way too low power because PD endpoints are often (I am not saying always) somewhat more variable both between and within subjects.


» is it will be in accordance with the regulatory requirement?

There is no specific requirement telling you what to do. But if you do something along the lines of thinking PK and PD have the same variability, an asssumption which to the best of my knowledge does not have any theoretical or practical backing, then you may be headed directly for a futile trial; you will be exposing volunteers to IMP without any truly justified anticipated benefit and that would be a strong ethical concern.

The fact that it is also a royal waste of money is of course only secondary.

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,462 posts in 4,487 threads, 1,514 registered users;
online 19 (0 registered, 19 guests [including 17 identified bots]).
Forum time: Sunday 20:58 UTC (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5